Filter Results
:
(315)
Show Results For
-
All HBS Web
(1,313)
- Faculty Publications (315)
Show Results For
-
All HBS Web
(1,313)
- Faculty Publications (315)
- April 2023
- Case
Elliott Management: Capital Allocation in Biopharma
By: Amitabh Chandra, Paul Clancy and Lauren Gunasti
The case explores the intersection of capital allocation and shareholder activism in the biopharmaceutical industry. As many biopharma companies face looming patent expirations for key medicines, the case asks the question of whether investing in R&D and M&A is an...
View Details
Keywords:
Finance;
Strategy;
Capital Allocation;
Biopharmaceutical Industry;
Shareholder Activism;
Investment Activism;
Resource Allocation;
Research and Development;
Business and Shareholder Relations;
Corporate Strategy;
Pharmaceutical Industry
Chandra, Amitabh, Paul Clancy, and Lauren Gunasti. "Elliott Management: Capital Allocation in Biopharma." Harvard Business School Case 623-045, April 2023.
- March 2023
- Case
Moderna
By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer, Kerry Herman, Allison J. Wigen and Dave Habeeb
This multimedia case follows the story of Moderna and its entry into vaccine development in the wake of the COVID-19 pandemic. In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19....
View Details
- March 2023
- Teaching Note
Hikma Pharmaceuticals Governance Journey
By: Suraj Srinivasan and Jonah Goldberg
Teaching Note for HBS Case No. 318108. The case opens with Said Darwazah, chairman and CEO of Hikma Pharmaceuticals, the multinational generics company, anticipating the company’s 2017 AGM and reflecting on changes made over the previous year to address concerns...
View Details
Keywords:
Jordan;
Emerging Market;
Private Sector;
For-profit Firms;
Boards Of Directors;
Pharmaceuticals;
Remuneration;
Shareholder Engagement;
Corporate Governance;
Governing and Advisory Boards;
Business and Shareholder Relations;
Executive Compensation;
Business Growth and Maturation;
Pharmaceutical Industry;
Jordan
- March 2023
- Case
Roche: ESG and Access to Healthcare
By: George Serafeim, Susanna Gallani and Benjamin Maletta
In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first ESG investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal to double the number of patients that...
View Details
Keywords:
ESG (Environmental, Social, Governance) Performance;
Sustainable Finance;
Growth Strategy And Execution;
Sustainability Targets;
Impact Evaluation;
Healthcare Access;
Healthcare Innovation;
Healthcare Systems;
Healthcare Operations;
Finance;
Strategy;
Health Testing and Trials;
Health Care and Treatment;
Growth Management;
Measurement and Metrics;
Innovation Strategy;
Corporate Social Responsibility and Impact;
Pharmaceutical Industry;
Pharmaceutical Industry;
Switzerland;
North America;
Europe;
Asia;
Latin America;
Africa
Serafeim, George, Susanna Gallani, and Benjamin Maletta. "Roche: ESG and Access to Healthcare." Harvard Business School Case 123-075, March 2023.
- January 2023 (Revised August 2023)
- Case
Veeva Systems and the Transformation to a Public Benefit Corporation
By: Ranjay Gulati and Allison M. Ciechanover
Peter Gassner, the co-founder and CEO of Veeva Systems, steered the company through rapid scaling from its launch in 2007 to 2022. Year after year, the company had exceeded expectations, with its market capitalization reaching $50 billion at its peak. By 2022, the...
View Details
- January 2023
- Teaching Note
The Opioid Settlement and Executive Pay at AmerisourceBergen
By: Suraj Srinivasan and Li-Kuan Ni
Teaching Note for HBS Case No 122-014. In 2020, AmerisourceBergen Corporation, a Fortune 50 company in the drug distribution industry, agreed to settle thousands of lawsuits filed nationwide against the company for its opioid distribution practices that critics alleged...
View Details
Keywords:
Opioids;
Shareholder Activism;
Investment Activism;
Corporate Accountability;
Corporate Governance;
Governance Compliance;
Governance Controls;
Executive Compensation;
Risk Management;
Corporate Social Responsibility and Impact;
Business and Shareholder Relations;
Business and Stakeholder Relations;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
United States;
West Virginia;
Tennessee;
Ohio;
Pennsylvania
- January 2023
- Case
Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery
By: Regina Herzlinger and Brian Walker
What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful...
View Details
Keywords:
Product Development;
Leadership;
Health Testing and Trials;
Research and Development;
Risk and Uncertainty;
Financial Condition;
Partners and Partnerships;
Pharmaceutical Industry
Herzlinger, Regina, and Brian Walker. "Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery." Harvard Business School Case 323-045, January 2023.
- November 2022 (Revised April 2024)
- Case
Martine Rothblatt and United Therapeutics: A Series of Implausible Dreams
By: Debora L. Spar and Julia M. Comeau
In 1990, satellite expert and Sirius XM founder Martine Rothblatt was determined to save the life of her seven-year-old daughter, Jenesis, who was diagnosed with a terminal illness called Pulmonary Arterial Hypertension (PAH). At the time, there was little medication...
View Details
Keywords:
Pharmaceutical Companies;
Technological And Scientific Innovation;
Organ Donation;
Health Care and Treatment;
Health Disorders;
Innovation and Invention;
Pharmaceutical Industry;
Pharmaceutical Industry;
United States;
District of Columbia
Spar, Debora L., and Julia M. Comeau. "Martine Rothblatt and United Therapeutics: A Series of Implausible Dreams." Harvard Business School Case 323-039, November 2022. (Revised April 2024.)
- October 2022
- Supplement
The SAH Group: The Time is Right, Instructor Spreadsheet
By: Juan Alcacer and Alpana Thapar
In January 2021, Jalila Mezni, CEO of the SAH Group, was preparing to present the company’s future growth plans to its board of directors. The Tunisian company was a leading producer and distributor of personal care and packaged hygiene products. In 2019, it expanded...
View Details
- October 2022
- Supplement
The SAH Group: The Time is Right, Spreadsheet Supplement
By: Juan Alcacer and Alpana Thapar
In January 2021, Jalila Mezni, CEO of the SAH Group, was preparing to present the company’s future growth plans to its board of directors. The Tunisian company was a leading producer and distributor of personal care and packaged hygiene products. In 2019, it expanded...
View Details
- October 2022
- Case
Cost Plus Drugs
By: Alexander MacKay and James Barnett
In September 2022, Mark Cuban Cost Plus Drugs Company CEO Alex Oshmyansky considered the future of the company. Cost Plus Drugs was a retailer for more than 340 generic oral medications, selling their drugs at significantly lower prices than typical pharmacies....
View Details
Keywords:
Business Ventures;
Decision Making;
Entrepreneurship;
Ethics;
Health;
Markets;
Social Enterprise;
Society;
Strategy;
Health Care and Treatment;
Business Divisions;
Factories, Labs, and Plants;
Pharmaceutical Industry;
Pharmaceutical Industry;
United States;
Texas
MacKay, Alexander, and James Barnett. "Cost Plus Drugs." Harvard Business School Case 723-362, October 2022.
- October 2022 (Revised January 2024)
- Case
mPharma: Scaling Access to Affordable Primary Care in Africa
By: Regina E. Herzlinger and Ben Creo
mPharma hopes to scale up to create the largest pan-African healthcare company ever to provide much-needed primary care in retail pharmacies; a reliable, fairly priced supply of drugs; and micro-insurance for drugs. They must prioritize launching a telemedicine...
View Details
Keywords:
Africa;
Pharmaceutical Companies;
Pharmacy Benefit Manager;
Health Care;
Health Care And Treatment;
Health Care Costs;
Health Care Delivery;
Health Care Entrepreneurship;
Telehealth;
Health Equity;
Corporate Strategy;
Social Entrepreneurship;
Equity;
Growth and Development Strategy;
Expansion;
Product Launch;
Customer Value and Value Chain;
Social Enterprise;
Multinational Firms and Management;
Pharmaceutical Industry;
Pharmaceutical Industry;
Africa
Herzlinger, Regina E., and Ben Creo. "mPharma: Scaling Access to Affordable Primary Care in Africa." Harvard Business School Case 323-033, October 2022. (Revised January 2024.)
- September 2022 (Revised November 2022)
- Case
The Uyghur Forced Labor Prevention Act: Forced Labor and Genocide in U.S.-China Relations
By: Jeremy Friedman and David Lane
On June 21, 2022, the Uyghur Forced Labor Prevention Act (UFLPA) went into effect, requiring companies to prove that goods imported from the People’s Republic of China were not made with forced labor. The bill was a reaction to reports of products being made with...
View Details
Keywords:
Ethics;
Multinational Firms and Management;
Globalized Markets and Industries;
Governing Rules, Regulations, and Reforms;
Policy;
Government Legislation;
International Relations;
Labor;
Wages;
Law Enforcement;
Law;
Rights;
Operations;
Supply Chain Management;
Business and Government Relations;
Agriculture and Agribusiness Industry;
Manufacturing Industry;
Mining Industry;
China;
United States
Friedman, Jeremy, and David Lane. "The Uyghur Forced Labor Prevention Act: Forced Labor and Genocide in U.S.-China Relations." Harvard Business School Case 723-001, September 2022. (Revised November 2022.)
- 2023
- Working Paper
Scoring and Funding Breakthrough Ideas: Evidence from a Global Pharmaceutical Company
By: Joshua Krieger, Ramana Nanda, Ian Hunt, Aimee Reynolds and Peter Tarsa
We study resource allocation to early-stage ideas at an internal startup program of
one the largest pharmaceutical firms in the world. Our research design enables us to
elicit every evaluator’s scores across five different attributes, before seeing how they
would...
View Details
Keywords:
Project Selection;
Pharmaceuticals;
Financing Innovation;
Resource Allocation;
Innovation and Invention;
Research and Development
Krieger, Joshua, Ramana Nanda, Ian Hunt, Aimee Reynolds, and Peter Tarsa. "Scoring and Funding Breakthrough Ideas: Evidence from a Global Pharmaceutical Company." Harvard Business School Working Paper, No. 23-014, August 2022. (Revised November 2023.)
- June 2022
- Case
The SAH Group: The Time is Right
By: Juan Alcacer and Alpana Thapar
In January 2021, Jalila Mezni, cofounder and CEO of the SAH Group, was preparing to present the company’s future growth plans to its board of directors. The Tunisian company was a leading producer and distributor of personal care and packaged hygiene products. In 2019,...
View Details
Keywords:
Growth Management;
Expansion;
Business Divisions;
Product Positioning;
Brands and Branding;
Competition;
Presentations;
Consumer Products Industry;
Tunisia;
Kenya
Alcacer, Juan, and Alpana Thapar. "The SAH Group: The Time is Right." Harvard Business School Case 722-357, June 2022.
- April 2022
- Teaching Note
CVS Health: Prescription for Transformation
By: Rosabeth Moss Kanter and Catarina Martinez
In 2021, new CEO Karen Lynch (named the most powerful woman in business) considered the next transformation phase for CVS Health (a Fortune 5 corporate giant). The 2018 acquisition of Aetna insurance brought her to the company as part of its long evolution from a...
View Details
Keywords:
Health;
COVID-19 Pandemic;
Primary Care;
Leadership;
Change Management;
Women Executives;
Retail;
Pharmacy;
Pharmacy Benefit Manager;
Clinical Trials;
Vaccination;
Acquisition;
Innovation and Invention;
Transformation;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
United States
- March 2022
- Case
GrowSari (A): Design for the Last Mile Customer
By: Brian Trelstad, Cam Carag and Michi Ferreol
Reymund (ER) Rollan and Shivapratim (Shiv) Choudhury, founders of the digital technology platform GrowSari, were at a crossroads. The feedback from their initial product roll-out were not what they had expected, and they needed to decide how to proceed. The pair,...
View Details
Keywords:
Fast Moving Consumer Goods;
Product Launch;
Information Technology;
Analytics and Data Science;
Digital Platforms;
Retail Industry;
Consumer Products Industry;
Technology Industry;
Philippines
Trelstad, Brian, Cam Carag, and Michi Ferreol. "GrowSari (A): Design for the Last Mile Customer." Harvard Business School Case 322-036, March 2022.
- March 2022
- Supplement
GrowSari (B)
By: Brian Trelstad, Cam Carag and Michi Ferreol
Case supplement for HBS Case No. 322-036. Reymund (ER) Rollan and Shivapratim (Shiv) Choudhury, founders of the digital technology platform GrowSari, were at a crossroads. The feedback from their initial product roll-out were not what they had expected, and they needed...
View Details
Keywords:
Fast Moving Consumer Goods;
Product Launch;
Information Technology;
Analytics and Data Science;
Digital Platforms;
Retail Industry;
Consumer Products Industry;
Technology Industry;
Philippines
Trelstad, Brian, Cam Carag, and Michi Ferreol. "GrowSari (B)." Harvard Business School Supplement 322-037, March 2022.
- 2022
- Chapter
Crises and International Business
By: Geoffrey Jones
This chapter uses the intellectual journey of the author to suggest that crises have been the norm rather than the exception in the history of international business. Over the last 100 years world wars, regional conflicts, the Great Depression, and decolonization are...
View Details
Keywords:
Crisis;
Multinational Companies;
International Business;
Emerging Market;
Business History;
Multinational Firms and Management;
System Shocks;
War;
Emerging Markets;
Crisis Management
Jones, Geoffrey. "Crises and International Business." Chap. 2 in International Business in Times of Crisis. Vol. 16, edited by Rob van Tulder, Alain Verbeke, Lucia Piscitello, and Jonas Puck, 27–32. Progress in International Business Research. Bingley, UK: Emerald Publishing Limited, 2022.
- February 2022 (Revised November 2022)
- Case
Nuritas
By: Mitchell Weiss, Satish Tadikonda, Vincent Dessain and Emer Moloney
Nora Khaldi had built a technology “to unlock the power of nature” in the service of extending human lifespan and improving health, and now in April 2020 was debating telling her Board of Directors she wanted to put on ice some of her discoveries. Nuritas, the company...
View Details
Keywords:
Cash Burn;
Cash Flow Analysis;
Pharmaceutical Companies;
Founder;
Artificial Intelligence;
AI;
Entrepreneurship;
Health Testing and Trials;
Health Care and Treatment;
Decision Making;
Market Entry and Exit;
AI and Machine Learning;
Pharmaceutical Industry
Weiss, Mitchell, Satish Tadikonda, Vincent Dessain, and Emer Moloney. "Nuritas." Harvard Business School Case 822-080, February 2022. (Revised November 2022.)